Drazen Zigic AngioDynamics ( NASDAQ: ANGO ) Wednesday announced European CE Mark approval of the AlphaVac F18 85 System for the non-surgical removal of thrombi or emboli from the pulmonary arteries and for the treatment of pulmonary embolism. “The CE Mark represents a major step forward in enhancing patient care and safety for endovascular therapies in the EU, a market with a higher prevalence of PE when compared to the United States,” said Laura Piccinini, AngioDynamics Senior Vice President/General Manager, Endovascular Therapies and International. The CE Mark for the AlphaVac F18 85 System expands treatment options for healthcare professionals in the EU by offering a tool that helps reduce thrombus burden and improve right ventricular function in patients with PE, the company said.
Source: Press Release More on AngioDynamics AngioDynamics: A Story To Monitor A Leaner AngioDynamics Is A High-Risk Execution-Driven Story AngioDynamics (ANGO) Q3 2024 Earnings Call Transcript AngioDynamics upgraded at Oppenheimer on pipeline progress AngioDynamics gets FDA clearance for pulmonary embolism treatment device.